In the past one week, the stock declined 9 per cent, as compared to 0.81 per cent fall in the S&P BSE Sensex. It slipped 20 per cent in a year, as against 5 per cent rise in the benchmark index. Further, in three years, the stock fell 4 per cent, while the Sensex rallied 39 per cent, during the same period.
Muted business growth in two years coupled with higher claims led by covid-19 resulted in the recent underperformance.
According to a report by Business Standard, India on June 7, reported an increase of 1,194 active coronavirus cases to take national count to 26,976. The country is fourty-seventh among the most affected countries by active cases. CLICK HERE FOR FULL REPORT
ICICI Lombard is India’s second largest non-life insurance player and one of the largest within the private sector with an overall market share of 8.1 per cent and 12.9 per cent market share in private general insurance space. Motor insurance remains the largest contributor to its premium at 46 per cent as of FY22.
For January-March 2022 quarter (Q4FY22), ICICI Lombard had reported a 9.53 per cent year-on-year (YoY) drop in net profit at Rs 313 crore, due to decline in third wave of Covid-19 and accounting principles that required the company to take the cost upfront. Meanwhile, the company had posted profit of Rs 346 crore in a year ago quarter.
That apart, underwriting losses of the insurer also widened in the quarter to Rs 309 crore from Rs 91 crore, a year ago.
The company paid claims to the tune of Rs 1,915 crore in Q4FY22, up 15 per cent from Rs 1,665 crore, in the year ago period. In the preceding quarter (Q3FY22), it had paid claims of Rs 2,083 crore.
According to analysts at Ashika Stock Broking, the company is a natural beneficiary of pick-up in non-life insurance space given huge under penetration. "Traditionally, the company has concentrated into business segments with lower loss ratios like motor own damage (OD) and third party (TP). However, loss ratios have been higher off -late due to Motor TP losses as well as higher expenses and higher investment for expansion of retail health network," the brokerage firm said.
The company's combined ratio stood at 103.2 per cent in Q4FY22 versus 99.8 per cent in FY21. The management expects COR to remain above 100 per cent as they on growth and expansion of market share. However, a strong investment book of Rs 38,786 crore in FY22 and realized return of 8.45 per cent is expected to aid earnings.
Moreover, with ~81 per cent of investments in debt, analysts believe that there is a scope for higher realized returns, with turn in interest rate cycle. Besides, synergy benefits from Bharti Axa’s product profile would flow in terms of operating efficiency coupled with pick-up in the industry volume.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in